|
Dec 5
|
UPDATE 3-Merck KGaA suffers major blow as MS drug fails in late-stage trials
|
|
Dec 4
|
UPDATE 1-Blackstone explores sale of Anthos Therapeutics -sources
|
|
Dec 4
|
Blackstone explores sale of Anthos Therapeutics -sources
|
|
Dec 1
|
Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More
|
|
Nov 30
|
25 Most Expensive Countries in the World to Raise a Child
|
|
Nov 30
|
Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?
|
|
Nov 29
|
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
|
|
Nov 29
|
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
|
|
Nov 28
|
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
|
|
Nov 28
|
FDA investigating cancer risk linked to CAR-T cell therapy
|
|
Nov 28
|
Novartis: CEO needs to convince over long-term prospects
|
|
Nov 28
|
Novartis bought his first startup for $3.9 billion. Now this physicist is trying to sell Europe on a new generation of nuclear energy
|
|
Nov 28
|
3 Large Drug Stocks That Have Outperformed Industry YTD
|
|
Nov 28
|
Novartis sees brighter sales future as R&D revamp continues
|
|
Nov 28
|
Trending tickers: Rolls-Royce | Novartis | EasyJet | Barclays
|
|
Nov 28
|
Novartis Raises Mid-Term Sales Growth Targets
|
|
Nov 28
|
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
|
|
Nov 27
|
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
|
|
Nov 26
|
12 Best Diabetes Stocks To Buy Now
|
|
Nov 9
|
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
|